Internet-based System for Cancer Patients to Self-report Toxicity

Learn more about:
Related Clinical Trial
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance Integrated Cancer Repository for Cancer Research Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function Sexual Rehabilitation Programme After Radiotherapy for Gynaecological Cancer Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer Internet-based System for Cancer Patients to Self-report Toxicity Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy Lymphoscintigraphy in Patients With Vaginal Cancer Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Pelvic Fractures and Radiation Therapy for Cervical Cancer Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Brief Title

Internet-based System for Cancer Patients to Self-report Toxicity

Official Title

Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life

Brief Summary

      Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue,
      diarrhea, constipation, or shortness of breath. These symptoms may be due to the cancer
      itself, or due to treatments like chemotherapy drugs or radiation therapy. Doctors and nurses
      often ask patients about their symptoms, because an important part of cancer treatment is to
      make patients feel as well as possible. If patients do not feel well, the investigators may
      need to change the way the investigators are treating you or prescribe therapies that will
      decrease your symptoms. The best way to find out how you are feeling is to ask you directly.

      However, during your time between appointments the investigators may not be able to ask you
      how you are feeling on a regular basis. In addition, even at an appointment, there may be
      symptoms that the investigators do not have a chance to discuss.

      The investigators are interested in developing new ways to ask patients about how they are
      feeling, using the Internet. A special new website called STAR ("Symptom Tracking and
      Reporting for Patients") has been developed to help patients record this information, so that
      their doctors and nurses can review it during clinic appointments. This study is designed to
      help us see if STAR is a helpful way for us to keep track of information about patients'
      symptoms and quality of life.

Detailed Description

      This pilot study will assess patient use of STAR (Symptom Tracking and Reporting for
      Patients), an online system designed for cancer patients to self-record toxicity-related
      symptoms based on NCI Common Terminology Criteria for Adverse Events v3.0, performance status
      by ECOG criteria, global quality of life by the EuroQOL 5-D assessment tool, emergency room
      visits, and survival. Secondary outcomes will include patient assessment of the usefulness of
      STAR, clinician perceptions of the potential value of STAR in routine clinical practice, and
      an evaluation of whether STAR improves the patient experience of care as assessed by
      satisfaction measures.

Study Type


Primary Outcome

To evaluate patient willingness to use STAR (Symptom Tracking and Reporting for Patients), an Internet-based system for cancer patients to self-report common toxicity symptoms, performance status, and quality of life.

Secondary Outcome

 To measure patient assessments of the usefulness of STAR, and to measure clinician perceptions of the potential value of STAR in routine outpatient cancer care.


Cervical Cancer



Study Arms / Comparison Groups

Description:  If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2004

Completion Date

January 2017

Primary Completion Date

January 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Age >18 years

          -  Diagnosis of gynecologic (ovarian; cervical; uterine; primary peritoneal), lung
             (non-small cell; small cell), gastrointestinal (colorectal, rectal, gastric,
             esophageal, GI neuroendocrine, small intestine malignancy, pancreatic,
             hepatocellular), breast, bladder cancer or prostate malignancy

          -  Receiving primary medical oncology care at MSKCC medical oncology outpatient clinics

          -  Receiving cytotoxic chemotherapy not on a clinical trial (or a new hormonal therapy in
             the case of prostate cancer patients only), with treatment expected to continue for at
             least four weeks from the time of enrollment

          -  Signed informed consent and Research Authorization

        Exclusion Criteria:

          -  ECOG performance status greater than 2

          -  Unable to read and comprehend English language text




18 Years - N/A

Accepts Healthy Volunteers



Ethan Basch, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Memorial Sloan Kettering Cancer Center

Study Sponsor

Ethan Basch, MD, Principal Investigator, Memorial Sloan Kettering Cancer Center

Verification Date

January 2017